DrugIn clinical trials
Zolacabtagene autoleucel
zolacabtagene autoleucel
Investigational CD19 CAR-T therapy (Bristol Myers Squibb, BMS-986353) studied in autoimmune diseases. Phase 1 Breakfree-2 multiple sclerosis cohorts (66 patients, MSToronto 2026, interim, single arm): CRS 42.4%, ICANS 7.6%; one fatal septic pneumonia after data cutoff. Not approved.
Also in the catalogue
- DivarasibDrug
- Insulin icodecDrug
- Liu J, Yi T, Xing P, et al. Trial of Endovascular Therapy for Mild Stroke with Large-Vessel Occlusion (MILD-MT). N Engl J Med, 2026Publication
- Skoulidis F, Ahn MJ, Gadgeel S, et al. Divarasib as Compared with Sotorasib or Adagrasib in KRAS G12C-Mutated NSCLC (Krascendo 1). N Engl J Med, 2026Publication
- ЛорундростатDrug
- Мебуфотенин (5-MeO-DMT, BPL-003)Drug
Scales
Identifiers
- INN
- zolacabtagene autoleucel
Details
- Status
- In clinical trials
- Class
- Autologous CD19-directed CAR-T cell therapy
A catalog card describes research; it is not medical advice. Decisions about treatment are made with a doctor.